Use of sanglifehrin macrocyclic analogues as anticancer compounds
US10857150B2 · kind B2 · utility
0Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 17, 2017 |
| Grant date | Dec 8, 2020 |
| Priority date | — |
| Expiry date | Nov 17, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D498/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to sanglifehrin macrocyclic analogues according to Formula (I), particularly for use in treatment of cancer, especially liver cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.